Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Migita, Kiyoshi ^a,b   Akeda, Yukihiro ^c   Akazawa, Manabu ^d   Tohma, Shigeto ^a   Hirano, Fuminori ^a   Ideguchi, Haruko ^a   Matsumura, Ryutaro ^a   Suematsu, Eiichi ^a   Miyamura, Tomoya ^a   Mori, Shunsuke ^a   Fukui, Takahiro ^a   Izumi, Yasumori ^a   Iwanaga, Nozomi ^a   Tsutani, Hiroshi ^a   Saisyo, Kouichirou ^a   Yamanaka, Takao ^a   Ohshima, Shiro ^a   Sugiyama, Takao ^a   Kawabe, Yojiro ^a   Katayama, Masao ^a   Suenaga, Yasuo ^a   Okamoto, Akira ^a   Ohshima, Hisaji ^a   Okada, Yasumasa ^a   Ichikawa, Kenji ^a   Yoshizawa, Shigeru ^a   Kawakami, Kenji ^a   Matsui, Toshihiro ^a   Furukawa, Hiroshi ^a   Oishi, Kazunori ^e   more..

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOMALATE; BUCILLAMINE; C REACTIVE PROTEIN; IMMUNOGLOBULIN G ANTIBODY; METHOTREXATE; PENICILLAMINE; PLACEBO; PNEUMOCOCCUS VACCINE; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; ANTIRHEUMATIC AGENT; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G;

ANTIBODY RESPONSE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MONOTHERAPY; OPSONIZATION; OUTCOME ASSESSMENT; PATIENT CODING; PNEUMOCOCCAL INFECTION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEROTYPE; VACCINATION; AGED; ARTHRITIS, RHEUMATOID; BLOOD; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED;

AGED; ANTIBODIES, BACTERIAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; TACROLIMUS;

EID: 84933503520     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0662-x     Document Type: Article

References (33)

1. Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am. 1997;23:219-37.
2. Glück T, Müller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 2008;46:1459-65.
3. Brezinschek HP, Hofstaetter T, Leeb BF, Haindl P, Graninger WB. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol. 2008;20:295-9.
4. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414-22.
5. van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011;10:341-52.
6. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45:106-11.
7. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor aα, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66:1016-26.
8. Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15:R171.
9. Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72:1362-6.
10. Kaminuma O. Selective inhibitors of nuclear factor of activated T cells: potential therapeutic drugs for the treatment of immunological and inflammatory diseases. Inflamm Allergy Drug Targets. 2008;7:35-40.
11. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol. 2005;53:S206-13.
12. Lindemann M, Heinemann FM, Horn PA, Witzke O. Immunity to pneumococcal antigens in kidney transplant recipients. Transplantation. 2010;90:1463-7.
13. van Gestel AM, Prevoo ML, Van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism Criteria. Arthritis Rheum. 1996;39:34-40.
14. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8:266-72.
15. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514-9.
16. World Health Organization Pneumococcal Serology Reference Laboratories at the Institute of Child Health, University College London, UK, and the Department of Pathology, University of Alabama, Birmingham, AL, USA. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). www.vaccine.uab.edu/ELISAProtocol(89SF).pdf.
17. Burton RL, Nahm MH. Development and validation of a four fold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006;13:1004-9.
18. Nahm MH, Burton RL. Protocol for multiplexed opsonophagocytic killing assay (UAB-MOPA) for antibodies against Streptococcus pneumoniae. www.vaccine.uab.edu/UAB-MOPA.pdf.
19. Takeuchi T, Kawai S, Yamamoto K, Harigai M, Ishida K, Miyasaka N. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2014;24:8-16.
20. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;315:1318-27.
21. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol. 1992;10:519-60.
22. Singer NG, McCune WJ. Update on immunosuppressive therapy. Curr Opin Rheumatol. 1998;10:169-73.
23. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187:1639-45.
24. Lindemann M, Heinemann FM, Horn PA, Witzke O. Long-term response to vaccination against pneumococcal antigens in kidney transplant recipients. Transplantation. 2012;94:50-6.
25. Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients-three year follow-up of a randomized trial. Am J Transplant. 2007;7:633-8.
26. Broeders EN, Wissing KM, Ghisdal L, Lemy A, Hoang AD, Vereerstraeten P, et al. Large decrease of anti-tetanus anatoxin and anti-pneumococcal antibodies at one year after renal transplantation. Clin Nephrol. 2013;79:313-7.
27. Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007;19:238-45.
28. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008;47:1328-38.
29. Lee CJ, Lee LH, Frasch CE. Protective immunity of pneumococcal glycoconjugates. Crit Rev Microbiol. 2003;29:333-49.
30. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol. 1995;13:655-92.
31. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther. 2007;9:R38.
32. Oishi K, Yoshimine H, Watanabe H, Watanabe K, Tanimura S, Kawakami K, et al. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. Respirology. 2006;11:429-36.
33. Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:499-505.